IBCL-054 The Effects of an mRNA COVID-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans

Arthur Frankel; Tazio Capozzola; Raiees Andrabi; Chul Ahn; Dennis Burton

doi:10.1016/S2152-2650(22)01548-8

IBCL-054 The Effects of an mRNA COVID-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans

Arthur Frankel, Tazio Capozzola, Raiees Andrabi, Chul Ahn, Dennis Burton

Research output: Contribution to journal › Article › peer-review

Abstract

Serum antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein are surrogate markers of immune response. We evaluated antibody levels pre and post third vaccine (booster) and compared responses among different cancer-bearing and normal veterans. Both total and neutralizing antibody levels increased in most subjects after the booster, but the frequency and magnitude of responses were lower in patients with B-cell malignancies undergoing therapy. Neutralizing antibody responses to omicron variants were reduced relative to wild-type and other variants. Additional prevention and prophylactic measures are warranted for poor vaccine responders.

Original language	English (US)
Pages (from-to)	S383-S384
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
DOIs	https://doi.org/10.1016/S2152-2650(22)01548-8
State	Published - Oct 2022

Keywords

B-cell malignancies
IBCL
antibodies
cancer
coronavirus
vaccine

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/S2152-2650(22)01548-8

Cite this

@article{d35da81261364f778dcbb193d08ff120,

title = "IBCL-054 The Effects of an mRNA COVID-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans",

abstract = "Serum antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein are surrogate markers of immune response. We evaluated antibody levels pre and post third vaccine (booster) and compared responses among different cancer-bearing and normal veterans. Both total and neutralizing antibody levels increased in most subjects after the booster, but the frequency and magnitude of responses were lower in patients with B-cell malignancies undergoing therapy. Neutralizing antibody responses to omicron variants were reduced relative to wild-type and other variants. Additional prevention and prophylactic measures are warranted for poor vaccine responders.",

keywords = "B-cell malignancies, IBCL, antibodies, cancer, coronavirus, vaccine",

author = "Arthur Frankel and Tazio Capozzola and Raiees Andrabi and Chul Ahn and Dennis Burton",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = oct,

doi = "10.1016/S2152-2650(22)01548-8",

language = "English (US)",

volume = "22",

pages = "S383--S384",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

}

TY - JOUR

T1 - IBCL-054 The Effects of an mRNA COVID-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans

AU - Frankel, Arthur

AU - Capozzola, Tazio

AU - Andrabi, Raiees

AU - Ahn, Chul

AU - Burton, Dennis

PY - 2022/10

Y1 - 2022/10

N2 - Serum antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein are surrogate markers of immune response. We evaluated antibody levels pre and post third vaccine (booster) and compared responses among different cancer-bearing and normal veterans. Both total and neutralizing antibody levels increased in most subjects after the booster, but the frequency and magnitude of responses were lower in patients with B-cell malignancies undergoing therapy. Neutralizing antibody responses to omicron variants were reduced relative to wild-type and other variants. Additional prevention and prophylactic measures are warranted for poor vaccine responders.

AB - Serum antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein are surrogate markers of immune response. We evaluated antibody levels pre and post third vaccine (booster) and compared responses among different cancer-bearing and normal veterans. Both total and neutralizing antibody levels increased in most subjects after the booster, but the frequency and magnitude of responses were lower in patients with B-cell malignancies undergoing therapy. Neutralizing antibody responses to omicron variants were reduced relative to wild-type and other variants. Additional prevention and prophylactic measures are warranted for poor vaccine responders.

KW - B-cell malignancies

KW - IBCL

KW - antibodies

KW - cancer

KW - coronavirus

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85138154383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138154383&partnerID=8YFLogxK

U2 - 10.1016/S2152-2650(22)01548-8

DO - 10.1016/S2152-2650(22)01548-8

M3 - Article

C2 - 36164097

AN - SCOPUS:85138154383

SN - 2152-2650

VL - 22

SP - S383-S384

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -

IBCL-054 The Effects of an mRNA COVID-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this